GlaxoSmithKline S.p.A. (GSK Italy), the Italian unit of global pharmaceutical giant GlaxoSmithKline. GSK Italy promotes and sells the therapeutic products of its parent company in the Italian market. The company also makes antibiotics, vaccines, and other injectable drugs at its manufacturing facilities in Parma and Verona, and it has a Milan-based division that sells consumer health care products and over-the-counter drugs. In addition, GSK Italy boasts a research and development unit in Verona that targets neurological drug development, including treatments for depression, addiction, schizophrenia, and sleep disorders.

LGC (Holdings) Limited company provides chemical, DNA and other scientific analysis through four operating divisions: LGC forensics, life and food sciences, research and technology, and LGC standards. Its customers are involved in such areas as drug development, health care services, chemicals and petrochemicals, law enforcement, and environmental quality and maintenance. The company's LGC Prochem unit sells enzymes, proteins, reagents, and other laboratory supplies. Investment firm 3i Group owns about 30% of LGC, as does its employees.

Eczacibasi Pharmaceutical and Industrial Investment (formerly Eczacibasi Pharmaceuticals Manufacturing) helps to keep the residents of Turkey healthy. The company provides a variety of pharmaceutical and health care products, including vitamins, diagnostic substances, and personal care items. Eczacibasi Pharmaceutical has interests in prescription drug marketing and manufacturing firms, as well as health care supply distribution firms. It also sells generic drugs through a partnership with Zentiva (part of Sanofi-Aventis). The firm's real estate division invests in commercial properties. Founded in 1952, Eczacibasi Pharmaceutical is a subsidiary of family owned Turkish industrial group Eczacibasi Holding.

Antigenics was founded in 1994 and is headquartered in Lexington, Massachusetts. Antigenics Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases, primarily based on immunological approaches. Its products include Oncophage (vitespen), a patient-specific therapeutic cancer vaccine registered for use in the Russia Federation, as well as under review by the European Medicines Agency for the treatment of kidney cancer patients with earlier-stage disease. The company tested Oncophage in phase 3 clinical trials for the treatment of renal cell carcinoma and metastatic melanoma; and phase 1 and phase 2 clinical trials for various indications, as well as in phase 2 clinical trial for the treatment of recurrent glioma, a type of brain cancer. Its product candidate portfolio also includes QS-21 Stimulon adjuvant, which is used in various vaccines under development in trials for diseases, such as hepatitis, human immunodeficiency virus, influenza, cancer, Alzheimer's disease, malaria, and tuberculosis; AG-707, a therapeutic vaccine program for the treatment of genital herpes; and Aroplatin, a liposomal chemotherapeutic for the treatment of solid malignancies and B-cell lymphomas. The company was formerly known as Antigenics L.L.C. and changed its name to Antigenics, Inc. in February 2000.

Nutrition 21, Inc. company was founded in 1983 and is headquartered in Purchase, New York. Nutrition 21, Inc., a nutritional bioscience company, develops, markets, and distributes proprietary and clinically substantiated nutritional supplements in the United States. The company sells Chromax branded chromium picolinate to vitamin and supplement and food manufacturers and marketers, as well as directly to retailers for use in human and animal nutrition products. It also develops and commercializes Diabetes Essentials, a proprietary, non-prescription, insulin sensitizer for people with type 2 diabetes. In addition, the company offers a portfolio of health and wellness products under the Iceland Health Maximum Strength Omega-3, Iceland Health Joint Relief, Iceland Health Advanced Memory Formula, Chromax chromium picolinate, Prescriptix Supplements, and Diabetes Essentials names. In addition, Nutrition 21, Inc. grants patent licenses to its ingredients to manufacturers and marketers of vitamin and mineral supplements.

Meridian Bioscience, Inc. company was founded in 1976 and is based in Cincinnati, Ohio. Meridian Bioscience, Inc. operates as an integrated life science company. The company primarily engages in the development, manufacture, sale, and distribution of diagnostic test kits primarily for respiratory, gastrointestinal, viral, and parasitic infectious diseases. Its diagnostic test kits utilize immunodiagnostic technologies, which test samples of blood, urine, stool, and other body fluids or tissues for the presence of antigens and antibodies of specific infectious diseases. The immunodiagnostic technologies include enzyme immunoassay, immunofluorescence, particle agglutination/aggregation, immunodiffusion, complement fixation, and chemical stains. The company also provides transport media that store and preserve specimen samples from patient collection to laboratory testing. In addition, Meridian Bioscience manufactures and distributes bulk antigens, antibodies, and reagents used by researchers and other diagnostic manufacturers. Further, it involves in the contract development and manufacture of proteins and other biologicals for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. Meridian Bioscience markets its diagnostic test kits through direct sales force and independent distributors to reference laboratories and hospitals primarily in the United States, Canada, Belgium, France, Holland, Italy, Africa, and the Middle East.

Zogenix is intent on alleviating that nasty migraine of yours. The biopharmaceutical company is focused on developing and commercializing central nervous system (CNS) and therapeutic pain medications. The company received FDA approval for its Sumavel DosePro (sumatriptan) candidate in 2009. The drug, previously known as Intraject, utilizes the company's needle-free drug delivery technology and administers sumatriptan for the relief of acute migraines and cluster headaches. Its other late-stage candidate, ZX002, is an oral controlled release formulation of hydrocodone, used for the treatment of chronic pain. Biotechnology veteran Cam Garner founded Zogenix in 2006.

Hi-Tech Pharmacal Co., Inc. was founded in 1982 and is based in Amityville, New York. Hi-Tech Pharmacal Co., Inc. (Hi-Tech) is a specialty manufacturer and marketer of prescription, over-the-counter (OTC) and nutritional products. The Company develops, manufactures and markets products in three categories: generics, prescription brands and OTC brands. It produce a range of products for various disease states, including asthma, bronchial disorders, dermatological disorders, allergies, pain, stomach, oral care, neurological disorders, glaucoma and other conditions. The Company’s generic products are primarily prescription items and include oral solutions and suspensions, topical creams and ointments, as well as nasal sprays. It also specializes in the manufacture of products in its sterile facility capable of producing liquid ophthalmic, otic and inhalation products. On February 27, 2009, the Company purchased substantially all of the assets of E. Claiborne Robins Company, Inc. doing business as, ECR Pharmaceuticals (ECR Pharmaceuticals or ECR).

NexMed, Inc. was founded in 1987 and is based in San Diego, California. NexMed, Inc. is a pharmaceutical and medical technology company with a focus on developing and commercializing therapeutic products based on its delivery systems. The Company focuses its efforts on new and topical pharmaceutical products based on a penetration enhancement drug delivery technology known as NexACT, which may enable an active drug to be better absorbed through the skin. The NexACT transdermal drug delivery technology is designed to enhance the absorption of an active drug through the skin, overcoming the skin’s natural barrier properties, and enabling high concentrations of the active drug to rapidly penetrate the desired site of the skin or extremity. In December 2009, the Company closed its acquisition of Bio-Quant, Inc., a research organization for in vitro and in vivo contract drug discovery and pre-clinical development services.

Bilcare, Inc., formerly ProClinical Pharmaceutical Services, is in favor of pharma. Bilcare, Inc. company, which also operates as Bilcare Global Clinical Services, is the American arm of parent company Bilcare Ltd. Its aim is to help pharmaceutical companies prepare for and conduct clinical trials. Bilcare's offerings include a wide range of analytical research, formulation development, manufacturing, and packaging and labeling of clinical supplies. Logistics services include the storage, distribution, reconciliation, and destruction of clinical trial supplies and investigational medicines. Its services encompass all levels of pharmaceutical drug trials.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.